LDX
Director Trades
| Date | Director | Value |
|---|
Company News
Lumos Diagnostics secures US government funding to develop groundbreaking FebriDx test
Lumos Diagnostics (ASX: LDX) has received significant US financial backing for its development of unique point-of-care diagnostic test technology. Lumos has been awarded approximately $4.3 million by a division of the US government’s health division to support a planned study and regulatory submission for the company’s FebriDx bacterial/non-bacterial test. FebriDx is designed to assess whether […]
Lumos Diagnostics extends distribution of FebriDx point-of-care test into Belgian market
Lumos Diagnostics (ASX: LDX) has extended a distribution agreement for its FebriDx rapid point-of-care test to include the Belgian market of US healthcare products supplier Henry Schein Medical. FebriDx is designed to identify viral versus bacterial acute respiratory infections within 10 minutes from a fingerstick blood sample and can be used to help accurately manage […]
Lumos Diagnostics secures additional US$5m for pioneering pre-term birth test development
Lumos Diagnostics (ASX: LDX) has received a second US$5 million payment from women’s health firm Hologic Inc under an intellectual property (IP) agreement signed between the two companies in January. The agreement grants Hologic an exclusive licence to use Lumos’ proprietary reader and point-of-care technologies in the development of its fetal fibronectin (fFN) test targeting […]
Market wrap: good news on jobs turns to bad news for shares
Once again, the Australian share market turned good economic news into a bad share performance as the ASX 200 index slumped to a three-month low of just 7042.3 points. Hot US jobs figures from ADP Research found that employers added 497,000 jobs in June – nearly double what was expected – driving most traders to […]
Lumos Diagnostics receives FDA clearance to market FebriDx in US
Lumos Diagnostics (ASX: LDX) has received clearance from the Food and Drug Administration (FDA) to market its FebriDx rapid point-of-care test in the US. The FDA determined the diagnostics test had demonstrated “substantial equivalence to the predicate device” cited in a 510(k) pre-market submission made by the company earlier this year. The product has been […]